Background and Objectives: Given the increasing prevalence of diabetes, there is a pressing need for effective management strategies. This study focuses on the first-year data since the Imeglimin's (oxidative phosphorylation blocker) launch, examining its utilization in India to assess its initial impact. The primary goals encompass comprehending the patients that benefit most from Imeglimin and determining its role in the present therapeutic scenario.
Methods:A retrospective analysis of 406 T2D patients prescribed Imeglimin was conducted using data from ten diverse centers across India, ensuring a representative sample. Patient profiles, including age, gender, and relevant demographics, were assessed. Prescription patterns were analyzed to glean insights into how Imeglimin is integrated with other diabetic medications, providing insights into its role as monotherapy or combination therapy.
Results:The investigation revealed that Imeglimin was predominantly administered to individuals aged 51-60 (average age of 54.1 years), glycated hemoglobin > 9 (40.8%), and exhibited a male predominance (56.4%). Notably, Imeglimin served as the first-line therapy in 66.4% patients and was frequently prescribed in conjunction with other oral antidiabetic medications (80.3%). Prescription patterns indicated a common combination of Imeglimin with biguanides, followed by dipeptidyl peptidase 4 (DPP-4) inhibitors, with the primary rationale for Imeglimin prescription being the presence of uncontrolled glucose levels.
Conclusion:Imeglimin shows promise as an effective treatment for T2D in the Indian context, showing efficacy across various age groups and particularly in cases of uncontrolled diabetes. Further long-term studies are recommended to assess its efficacy and safety profile over an extended period.
B. Saboo: None. M. Anuj: None. S. Ghosh: None. S.M. Patil: None.